Bank of America began coverage on shares of Cortexyme (NASDAQ:CRTX) in a research report report published on Monday, June 3rd, FirstToMarketsRatingsTable reports. The firm issued a neutral rating and a $28.00 price target on the biopharmaceutical company’s stock.
Separately, JMP Securities initiated coverage on Cortexyme in a research report on Monday, June 3rd. They set a mkt outperform rating and a $53.00 price objective for the company.
NASDAQ CRTX traded up $0.56 on Monday, hitting $38.61. The company’s stock had a trading volume of 56,005 shares, compared to its average volume of 119,118. Cortexyme has a 52-week low of $19.50 and a 52-week high of $47.50. The firm’s 50-day simple moving average is $28.39.
In other news, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.
Further Reading: What are different types of coverage ratios?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.